• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Sarepta Therapeutics (SRPT)

Common Shares
Sell: $16.72|Buy: $16.82|Change: 0.04 (0.24%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

Address

215 First Street
Suite 415
Cambridge
MA
USA
02142

Telephone

+1 617 274-4000

Website

https://www.sarepta.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Sarepta Therapeutics Inc Annual Report for 20262027-03-02T00:00:00
Sarepta Therapeutics Inc Fourth Quarter Earnings Conference Call for 20262027-02-25T16:30:00
Sarepta Therapeutics Inc Fourth Quarter Earnings Results for 20262027-02-25T00:00:00
Sarepta Therapeutics Inc Third Quarter Earnings Conference Call for 20262026-11-03T16:30:00
Sarepta Therapeutics Inc Third Quarter Earnings Results for 20262026-11-03T00:00:00
Sarepta Therapeutics Inc Second Quarter Earnings Results for 20262026-08-06T00:00:00
Sarepta Therapeutics Inc Annual General Meeting for 20262026-06-05T10:00:00
Sarepta Therapeutics Inc First Quarter Earnings Conference Call for 20262026-05-06T16:30:00
Sarepta Therapeutics Inc First Quarter Earnings Results for 20262026-05-06T00:00:00
TD Cowen 46th Annual Health Care Conference2026-03-03T13:50:00
Sarepta Therapeutics Inc Annual Report for 20252026-03-02T00:00:00

Previous key dates

NameKey Date
TD Cowen 46th Annual Health Care Conference2026-03-03T13:50:00
Sarepta Therapeutics Inc Annual Report for 20252026-03-02T00:00:00
Sarepta Therapeutics Inc Fourth Quarter Earnings Conference Call for 20252026-02-25T16:30:00
Sarepta Therapeutics Inc Fourth Quarter Earnings Result for 20252026-02-25T00:00:00
Sarepta EMBARK Study 3 Year Topline Results2026-01-26T08:30:00
44th Annual J.P. Morgan Healthcare Conference2026-01-12T12:00:00
Sarepta Therapeutics Inc Third Quarter Earnings Conference Call for 20252025-11-03T16:30:00
Sarepta Therapeutics Inc Third Quarter Earnings Results for 20252025-11-03T00:00:00
Sarepta Therapeutics Inc Second Quarter Earnings Results for 20252025-08-06T00:00:00
Sarepta Safety Update for ELEVIDYS and Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne2025-06-16T08:00:00
Sarepta Therapeutics Inc Annual General Meeting for 20252025-06-05T10:00:00
BofA Securities 2025 Healthcare Conference2025-05-14T11:40:00
Sarepta Therapeutics Inc First Quarter Earnings Conference Call for 20252025-05-06T16:30:00
Sarepta Therapeutics Inc First Quarter Earnings Result for 20252025-05-06T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.